The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning ...

Live-attenuated respiratory syncytial virus (RSV) vaccines are highly immunogenic among HIV-exposed uninfected (HEU) pediatric patients, according to results of a study published in Open Forum ...

Respiratory syncytial virus (RSV) is a common viral infection that may lead to serious complications in certain groups. Since 2023, vaccines are now available and are highly recommended ...

About 8 in 10 infants received respiratory syncytial virus protection during the 2023 to 2024 season, according to study findings.

The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV] vaccine) and Arexvy ® ( RSV vaccine, adjuvanted) has been updated to include a new warning regarding the risk of ...

In an annual shareholder letter earlier this month, Bancel described a recent “contraction” of the U.S. RSV market fueled by a limited vaccine recommendation from the CDC. In light of the ...

For immunocompromised individuals, antibody response to respiratory syncytial virus (RSV) vaccines is heterogeneous and about 40% do not seroconvert.

Demand for its COVID vaccine has been waning since the pandemic, while adoption of its RSV shot - its second approved product- has been slower than expected, forcing Moderna to cut costs.

On Tuesday, January 7, the FDA announced it would now be requiring GSK and Pfizer’s RSV vaccines to hold warnings of a risk of Guillain-Barré syndrome (GBS). This is after post market analysis ...

The CDC recommends RSV vaccines for all adults ages 75 and older and adults ages 60 – 74 who are at increased risk for severe RSV. There are two immunizations recommended for infants ...

antibody response to respiratory syncytial virus (RSV) vaccines is heterogeneous and about 40% do not seroconvert, according to a research letter published online December 30 in the Journal of the ...